Scarica l'app Stockscreener
79.57
0.54%
0.43
Dopo l'orario di chiusura:
79.57
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7MNews and Statistics - IndexBox
Nextech Trims Kymera at a Recent High — think Foolishly before acting. - Yahoo Finance
Aug Selloffs: What is the long term forecast for Kymera Therapeutics Inc stock2026 Market Sentiment & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Breakouts: What is Kymera Therapeutics Incs 5 year growth outlookPortfolio Return Report & Consistent Return Strategy Ideas - baoquankhu1.vn
Weekly Earnings: Is Kymera Therapeutics Inc currently under institutional pressure2026 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Holocene Advisors LP Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
KYMR: Jefferies Lowers Price Target but Maintains Buy Rating | KYMR Stock News - GuruFocus
Jefferies Financial Group Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
KYMR: Jefferies Lowers Price Target but Maintains Buy Rating | K - GuruFocus
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 earnings call transcript - MSN
Boxer Capital Management LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Checkpoint Capital L.P. - MarketBeat
Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside - Yahoo Finance
Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC - MarketBeat
Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals? - simplywall.st
Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada
KYMR: Advancing oral immunology therapies with robust pipeline and strong financial runway - TradingView
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union
Morgan Stanley maintains Kymera Therapeutics (KYMR) overweight recommendation - MSN
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat
Kymera Therapeutics COO Sells Shares Worth Over $2 Million - TradingView
Kymera (NASDAQ: KYMR) COO exercises 20,000 options and sells 25,758 shares - Stock Titan
Jeremy Chadwick reports KYMR transactions (NASDAQ: KYMR) including 20,000-option line - Stock Titan
Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN
Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget
Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan
A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change - Sahm
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance
Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
How (KYMR) Movements Inform Risk Allocation Models - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Profit Recap: How sensitive is Kymera Therapeutics Inc to inflationWeekly Volume Report & Reliable Entry Point Trade Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Has $10.91 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera (KYMR) Q4 2025 Earnings Call Transcript - AOL.com
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Insider Jared Gollob Sells 4,895 Shares - MarketBeat
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00 - MarketBeat
UBS Raises Price Target for Kymera Therapeutics (KYMR) to $128 | - GuruFocus
Kymera at TD Cowen Conference: Strategic Insights on Drug Programs - Investing.com
Commit To Purchase Kymera Therapeutics At $60, Earn 15.1% Annualized Using Options - Nasdaq
How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors - simplywall.st
Kymera Therapeutics (KYMR) Stock Analysis: Exploring a 30% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase (NASDAQ:KYMR) - Seeking Alpha
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology
Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Kymera Therapeutics (KYMR) - The Globe and Mail
[144] Kymera Therapeutics, Inc. SEC Filing - Stock Titan
Citigroup Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $120.00 - MarketBeat
Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Reaff - GuruFocus
Stephens raises Kymera Therapeutics price target to $100 on pipeline By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR): Analyst Raises Price Target to $100 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00 at Stephens - MarketBeat
TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans - Yahoo Finance
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 - MarketBeat
Kymera Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):